Literature DB >> 9057658

Mutations and loss of expression of a mismatch repair gene, hMLH1, in leukemia and lymphoma cell lines.

A Hangaishi1, S Ogawa, K Mitani, N Hosoya, S Chiba, Y Yazaki, H Hirai.   

Abstract

Defects in genes involved in DNA mismatch repair have been detected in both hereditary and sporadic tumors of colon, endometrium, and ovary and suggested to be associated with tumorigenesis. To investigate disruptions of the mismatch repair system in hematological malignancies, we examined alterations of the human mutL homologue 1 (hMLH1) gene, a member of the mismatch repair gene family, in a total of 43 human leukemia and lymphoma cell lines, by polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) and sequencing analyses. Mutations of the hMLH1 gene were detected in three cell lines established from lymphoid leukemias. Moreover, Northern and Western blot analyses showed that expression of hMLH1 transcript or protein was abrogated in these three leukemia cell lines. Further studies for microsatellite loci showed that these cell lines without hMLH1 expression showed microsatellite instability. This is the first report that describes mutations and inactivation of the hMLH1 gene in human leukemia cells, suggesting that disruption of DNA mismatch repair system may play an important role in the development of human lymphoid leukemias.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9057658

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

1.  Dimerization of MLH1 and PMS2 limits nuclear localization of MutLalpha.

Authors:  Xiaosheng Wu; Jeffrey L Platt; Marilia Cascalho
Journal:  Mol Cell Biol       Date:  2003-05       Impact factor: 4.272

2.  Loss of mutL homolog-1 (MLH1) expression promotes acquisition of oncogenic and inhibitor-resistant point mutations in tyrosine kinases.

Authors:  Lorraine Springuel; Elisabeth Losdyck; Pascale Saussoy; Béatrice Turcq; François-Xavier Mahon; Laurent Knoops; Jean-Christophe Renauld
Journal:  Cell Mol Life Sci       Date:  2016-07-19       Impact factor: 9.261

3.  Selective tumor cell death induced by irradiated riboflavin through recognizing DNA G-T mismatch.

Authors:  Yi Yuan; Yongyun Zhao; Lianqi Chen; Jiasi Wu; Gangyi Chen; Sheng Li; Jiawei Zou; Rong Chen; Jian Wang; Fan Jiang; Zhuo Tang
Journal:  Nucleic Acids Res       Date:  2017-09-06       Impact factor: 16.971

4.  Therapy-associated myelodysplastic syndrome with monosomy 7 arising in a Muir-Torre Syndrome patient carrying SETBP1 mutation.

Authors:  David Ullman; Erin Baumgartner; Nicholas Wnukowski; Gabe Koenig; Fady M Mikhail; Peter Pavlidakey; Deniz Peker
Journal:  Mol Clin Oncol       Date:  2017-12-08

5.  Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study.

Authors:  Terzah M Horton; Patrick A Thompson; Stacey L Berg; Peter C Adamson; Ashish M Ingle; M Eileen Dolan; Shannon M Delaney; Madhuri Hedge; Heidi L Weiss; Meng-Fen Wu; Susan M Blaney
Journal:  J Clin Oncol       Date:  2007-11-01       Impact factor: 44.544

6.  Extracolonic manifestations of lynch syndrome.

Authors:  Brian J Bansidhar
Journal:  Clin Colon Rectal Surg       Date:  2012-06

7.  Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity.

Authors:  Terzah M Horton; Gaye Jenkins; Debananda Pati; Linna Zhang; M Eileen Dolan; Albert Ribes-Zamora; Alison A Bertuch; Susan M Blaney; Shannon L Delaney; Madhuri Hegde; Stacey L Berg
Journal:  Mol Cancer Ther       Date:  2009-08-11       Impact factor: 6.261

8.  Thymic cancer in lynch syndrome: an unusual association.

Authors:  Deepali Pandey; David Scott Shepro
Journal:  BMJ Case Rep       Date:  2020-04-08

9.  Frameshift mutations of the hMSH6 gene in human leukemia cell lines.

Authors:  N Hosoya; A Hangaishi; S Ogawa; K Miyagawa; K Mitani; Y Yazaki; H Hirai
Journal:  Jpn J Cancer Res       Date:  1998-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.